{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-040033","form_type":"8-K","ticker":"LFST","cik":"0001845257","company_name":"LifeStance Health Group, Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.706199+00:00","generated_at":"2026-06-11T23:22:06.981541+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"LifeStance Q2 revenue up 24% to $259.6M; raises FY revenue guidance to $1.01-1.04B","bullets":["Q2 revenue $259.6M (+24% YoY); net loss $45.5M improved from $68.7M loss.","Adjusted EBITDA $14.1M (-3% YoY); Center Margin $73.0M (28.1% of revenue).","Total clinicians 6,132 (+17% YoY); net add 171 in Q2.","FY 2023 revenue guidance raised to $1.01-1.04B; reaffirms Adj. EBITDA $50-62M.","Q3 2023 guidance: revenue $250-260M, Adj. EBITDA $11-17M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-040033","json":"https://secwatch.observer/filing/0000950170-23-040033.json","markdown":"https://secwatch.observer/filing/0000950170-23-040033.md","text":"https://secwatch.observer/filing/0000950170-23-040033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1845257/000095017023040033/0000950170-23-040033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1845257/000095017023040033/lfst-20230809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T23:22:06.981541+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9a7fd7784a4d02aa7e92f540ce4ae21f945b92e2","claim":"LifeStance Health Group, Inc. reported second quarter ended June 30, 2023 results: revenue $259.6 million, net income $45.5 million. Guidance raised.","evidence_excerpt":"the second quarter ended June 30, 2023. (All results compared to prior-year comparative period, unless otherwise noted) Q2 2023 Highlights and FY 2023 Outlook • Total revenue of $259.6 million increased $50.1 million or 24% compared to total revenue of $209.5 million • Total clinicians of 6,132 up 17%, a sequential net increase of 171 in the second quarter • Net loss","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1845257/000095017023040033/0000950170-23-040033-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$259.6 million"},{"label":"Net income","value":"$45.5 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}